Australia's most trusted
source of pharma news
Posted 9 February 2021 AM
The TGA is conducting a public consultation that seeks "to understand potential obstacles and incentives to repurposing of prescription medicines that may influence a company's decision to extend an indication" for an existing medicine previously registered in Australia.
It hopes to hear from sponsors that wish to extend indications for an existing medicine either already approved overseas for the indication, for a less common disease, already accepted clinical practice albeit "off-label", or likely to be less commercially profitable.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.